Ticker: MRNA

Moderna

Pharma Healthcare Biotechnology

Price 136.62

Reco Sell Potential 41 Risk 73 Updated 2026-09-10

Official website

Forecast impact

negative

Target -40.7% target fill 168.7%

Reaction D5 +6.02% · D10 pending market trust

Impact Potential -4 · Risk +3 valid until 2026-10-03

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Moderna is a biotechnology company focused on developing messenger RNA (mRNA) therapeutics and vaccines. Its core products include the COVID-19 vaccine and various candidates for infectious diseases, cancer, and rare diseases. The company primarily generates revenue from vaccine sales, with a significant portion derived from government contracts and partnerships. Moderna's business segments include research and development, manufacturing, and commercialization of its mRNA-based products.

Investment Profile

The investment profile of Moderna is more aligned with growth investors, given its focus on innovative mRNA technology and potential future product pipeline. However, the high risk associated with its current financial performance and market volatility may deter conservative investors. The stock may appeal to those with a medium to long-term horizon who are willing to navigate potential fluctuations.

Category: Pharma Sector: Healthcare Industry: Biotechnology Investment style: Growth Horizon: Medium-term Company type: Blue Chip Company type: Market Leader Experience: Basic

Fundamental metrics (experimental) Updated: 2026-09-10

EPS (TTM) — earnings per share for the last 12 months, $: -7.98
Revenue QoQ — quarter-over-quarter revenue growth: -62.7%
EPS surprise: 60.9%
20d volatility: 39.5%

AI recommendation changes

Date	Before	After	Reason
2026-08-25	Hold	Sell	Weak fundamentals and high volatility raise significant concerns.
2026-08-23	Sell	Hold	High volatility and negative fundamentals raise concerns.
2026-08-21	Hold	Sell	scenario_deterioration
2026-08-15	Sell	Hold	Weak fundamentals and high risk limit upside potential.
2026-07-09	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-07-02	Sell	Hold	Strong recent performance, but fundamentals show weakness.
2026-06-23	Hold	Sell	Weak fundamentals and high volatility raise significant risk.
2026-06-19	Sell	Hold	Strong recent performance, but fundamentals show weakness.
2026-06-11	Hold	Sell	scenario_deterioration
2026-06-05	Sell	Hold	Weak fundamentals offset by recent price momentum.
2026-06-03	Hold	Sell	scenario_deterioration
2026-05-28	Sell	Hold	Weak fundamentals and high volatility raise concerns.
2026-05-16	Hold	Sell	scenario_deterioration
2026-05-08	—	Hold	Weak fundamentals and high volatility raise concerns.
2026-05-08	Hold	Hold	Компания Moderna демонстрирует значительный рост за последние 120 дней, однако отрицательный EPS и снижение выручки указывают на риски. Рекомендуется удерживать акции до получения более ясных сигналов о восстановлении.
2026-03-27	Sell	Hold	Компания Moderna демонстрирует сильный рост за последние 60 и 120 дней, однако отрицательный EPS и значительное снижение выручки в квартальном выражении указывают на риски. Рекомендуется удерживать акции до прояснения фи
2026-03-20	Hold	Sell	Компания испытывает значительное снижение выручки и отрицательный EPS, что указывает на финансовые проблемы. Текущая цена акций также значительно ниже недавних максимумов, что может свидетельствовать о дальнейшем падении
2026-02-08	Buy	Hold	Компания показывает сильный рост выручки и положительную динамику за последние 60 дней, что указывает на высокий потенциал. Однако отрицательный EPS и высокая волатильность требуют осторожности.
2026-01-30	Hold	Buy	Компания Moderna демонстрирует значительный рост выручки и положительную динамику акций за последние месяцы, что указывает на потенциал для дальнейшего роста. Однако отрицательный EPS и высокая волатильность требуют осто
2026-01-25	Buy	Hold	Компания Moderna демонстрирует сильный рост выручки и позитивные результаты по сюрпризам, однако отрицательный EPS и высокая волатильность акций указывают на значительные риски.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-09-03	UBS	Rating Downgraded	— → 81	150.81
2026-08-28	Argus Research	Update	— → 180	142.77
2026-08-24	Barclays	Target Raised	48 → 125	145.13
2026-08-20	UBS	Target Raised	50 → 150	174.38
2026-08-19	Goldman Sachs	Target Raised	67 → 120	174.38
2026-08-19	RBC Capital	Target Raised	45 → 130	151.3
2026-08-19	Loop Capital Markets	Update	— → 135	139.12
2026-08-19	D.A. Davidson	Target Lowered	— → 245	138.205
2026-07-21	Goldman Sachs	Target Raised	49 → 67	59.49
2026-07-20	Wolfe Research	Target Raised	— → 25	61.82
2026-07-08	Morgan Stanley	Target Raised	33 → 39	79.77
2026-07-07	RBC Capital	Target Raised	38 → 45	81.8
2026-06-26	Piper Sandler	Target Raised	69 → 77	67.66
2026-05-04	UBS	Target Raised	36 → 45	47.465
2026-05-04	RBC Capital	Target Raised	35 → 38	46.87
2026-05-01	Goldman Sachs	Target Raised	43 → 49	45.37
2026-05-01	Morgan Stanley	Target Raised	30 → 33	44.18
2026-03-03	Jefferies	Update	— → 37	49.83
2026-02-17	RBC Capital	Target Raised	25 → 30	42.54
2026-02-17	Evercore ISI	Target Raised	28 → 35	43.19
2026-02-17	Bernstein	Target Raised	35 → 45	42.23
2026-02-16	UBS	Target Raised	34 → 36	42.23
2026-02-16	Morgan Stanley	Target Raised	28 → 30	42.23

News Page 2 of 3

Stocks Making Significant Moves Premarket: Walmart, Coinbase, Moderna, Alibaba, and Others

08/20/2026, 05:37 AM business review Advance Auto Parts Wolfspeed Alibaba NetEase Coty Walmart Coinbase Moderna

Premarket trading saw significant movements in various stocks, with Walmart and Advance Auto Parts facing declines due to disappointing earnings, while crypto-related stocks surged following positive legislative developments.

U.S. President Donald Trump Criticizes Interest Rates and Promises Economic Warfare Against Iran

08/20/2026, 12:36 AM announcement finance Moderna

President Trump's recent comments on interest rates and economic policies have stirred market optimism, particularly in the cryptocurrency sector and technology stocks, while also highlighting ongoing economic pressures in the U.S. and escalating tensions with Iran.

U.S. Treasury Department Doubles Bond Purchases to Manage Rising Debt Exceeding $40 Trillion

08/19/2026, 06:36 PM announcement finance Nvidia Merck Moderna

The U.S. Treasury's decision to double its bond purchases aims to lower borrowing costs amid a surging national debt, which has now exceeded $40 trillion. This move is significant as it impacts both bond yields and stock market performance, while raising concerns about long-term fiscal sustainability.

Stocks Making Significant Midday Moves: Moderna Surges 120%, Pilgrim’s Pride Rallies 15%, Target Gains 5%

08/19/2026, 09:37 AM business review Pilgrim's Pride La-Z-Boy Marvell Technology Lowe's Companies Merck CoStar Group Alexandria Real Estate Coinbase Target Moderna

Midday trading saw significant stock movements, particularly for Moderna and Merck, following positive trial results for a cancer vaccine, while other companies like Pilgrim's Pride and Target also experienced notable gains.

Target (TGT) Reports $752 Million Earnings Boost from Tariff Refunds, Adjusts Full-Year Outlook

08/19/2026, 06:36 AM economy growth retail Target Moderna

Moderna's shares surged following positive results from its cancer vaccine trial, while rising bond yields are raising concerns about consumer loans and government debt. Investors should also note Target's earnings boost from tariff refunds and the implications of paused tariffs on Canadian goods.

Stocks to Watch: Moderna and Merck Surge on Positive Cancer Vaccine Trial Results, While Lowe’s and La-Z-Boy Face Declines

08/19/2026, 05:36 AM business review Mercury Systems La-Z-Boy Estee Lauder Lowe's Companies Analog Devices Toll Brothers Keysight Technologies Merck Moderna

Moderna and Merck's shares surged following positive results from a late-stage trial of their personalized cancer vaccine, while other companies like Keysight Technologies and Estee Lauder reported strong earnings, impacting their stock prices positively. Conversely, Lowe's and La-Z-Boy faced declines due to disappointing forecasts and earnings results.

Analysts Leerink Partners highlight promising results of Merck (MRK) and Moderna’s (MRNA) personalized cancer vaccine in late-stage trial

08/19/2026, 04:37 AM business research Analysts: analysts, Leerink Partners healthcare Merck Moderna

Merck and Moderna's personalized cancer vaccine has shown promising results in a late-stage trial for melanoma, potentially paving the way for a new treatment option and positively impacting both companies' stock prices.